In an international collaboration, researchers have determined that psychiatric disorders may have important molecular similarities that are not reflected in current diagnostic categories.
Dopamine agonists and prodrugs taken to treat Parkinson’s disease may cause impulse control disorders in over half the patients they are prescribed to.
Scientists have identified novel genes associated with a specific form of schizophrenia, which could potentially aid diagnosis and development of treatments.
According to a large study, individuals with Type 2 diabetes may have an increased risk of being diagnosed with Parkinson’s disease later in life.
Over a third of adults in the USA may be unknowingly using prescription medications that could increase the risk of depression and suicide.
An independent data monitoring committee has advised that lanabecestat is unlikely to meet primary endpoints, leading to the decision to discontinue trials.
A proof-of-concept study reveals that silibinin may reduce brain metastasis in mice and patients, providing a potential treatment option for secondary brain tumors.
For World Brain Tumor Day (8 June), Gene Barnett, a neurosurgeon at the Cleveland Clinic (OH, USA) discusses common perceptions around brain tumors and their work with ‘tumor-treating fields’.
This week’s industry news round-up reveals the latest updates around spinal muscular atrophy, Parkinson’s disease and acute stroke.